Patent Board Denies Review Of Patents Related To Natalizumab
(Decision re: ‘321 patent available. Document #16-161107-007Z.)
According to the board, contrary to assertions raised by petitioner Swiss Pharma International AG, it is unlikely that claims 1-4 of U.S. patent No. 8,349,321, claims 1, 3-7 and 9-12 of U.S. patent...
To view the full article, register now.